Edesa Biotech lifts base pay for its CEO, president and finance chief
Edesa Biotech raised base salaries for its CEO, president and CFO retroactively to July 1, 2026, according to TradingView citing SEC filings.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
Edesa Biotech has raised the yearly base pay of its chief executive Pardeep Nijhawan, president Michael Brooks and finance chief Peter Weiler. The increases apply from July 1, 2026, and were booked retroactively. According to TradingView, Nijhawan's base went from $357,696 to $657,423, Brooks's from $335,340 to $591,681, and Weiler's from $300,000 to $525,938. The company did not give a reason. Ninety percent of the monthly base salary that would otherwise be paid in cash is still granted as fully vested RSUs.
why it matters
This is a routine disclosure from a small biotech, not a change to financial results, so the direct market impact is limited. Investors may still read it as a sign of how management pay is structured, including the share of compensation paid in equity.
tags
instruments
sources
- Edesa Biotech raises salaries of CEO Pardeep Nijhawan, President Michael Brooks and CFO Peter Weiler — TradingView, 23 October 2026 at 21:33 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗